Next Article in Journal / Special Issue
Methods for Evaluating Cell-Specific, Cell-Internalizing RNA Aptamers
Previous Article in Journal
cGMP-Dependent Protein Kinase Inhibitors in Health and Disease
Previous Article in Special Issue
RNAi Therapeutic Platforms for Lung Diseases
Open AccessReview

RNAi Therapeutics in Autoimmune Disease

Department of Science and Mathematics, Cedarville University, 251 North Main Street, Cedarville, OH 45314, USA
Department of Oral and Maxillofacial Diagnostic Sciences, University of Florida College of Dentistry, 1600 SW Archer Rd, Gainesville, FL 32610, USA
Author to whom correspondence should be addressed.
Pharmaceuticals 2013, 6(3), 287-294;
Received: 31 December 2012 / Revised: 18 February 2013 / Accepted: 27 February 2013 / Published: 5 March 2013
(This article belongs to the Special Issue RNAi-Based Therapeutics)
Since the discovery of RNA interference (RNAi), excitement has grown over its potential therapeutic uses. Targeting RNAi pathways provides a powerful tool to change biological processes post-transcriptionally in various health conditions such as cancer or autoimmune diseases. Optimum design of shRNA, siRNA, and miRNA enhances stability and specificity of RNAi-based approaches whereas it has to reduce or prevent undesirable immune responses or off-target effects. Recent advances in understanding pathogenesis of autoimmune diseases have allowed application of these tools in vitro as well as in vivo with some degree of success. Further research on the design and delivery of effectors of RNAi pathway and underlying molecular basis of RNAi would warrant practical use of RNAi-based therapeutics in human applications. This review will focus on the approaches used for current therapeutics and their applications in autoimmune diseases, including rheumatoid arthritis and Sjögren’s syndrome. View Full-Text
Keywords: RNA interference; therapeutics; microRNA; small interfering RNA; autoimmune disease RNA interference; therapeutics; microRNA; small interfering RNA; autoimmune disease
MDPI and ACS Style

Pauley, K.M.; Cha, S. RNAi Therapeutics in Autoimmune Disease. Pharmaceuticals 2013, 6, 287-294.

Show more citation formats Show less citations formats

Article Access Map

Only visits after 24 November 2015 are recorded.
Back to TopTop